Abstract

This editorial reflects on the transformative decade of precision oncology, from the first FDA approval of imatinib for CML to the current landscape of CAR-T therapies and tumor-agnostic treatments. We outline editorial priorities for 2024-2026, emphasizing liquid biopsy standardization, real-world evidence integration, and equitable access to targeted therapies in low-income settings.